Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3062% above fair value
$315.34+16.79 (+5.62%)
Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –
Krystal Biotech pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Krystal Biotech's pe ratio was 38.7× on Nov 11, 2026, against 32.7× a year earlier. Over the last 3 years it ranged from 30.0× to 459.6×, with a median of 45.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 38.7× | +1.7 |
| 2025 | Dec 31, 2025 | 37.0× | −49.1 |
| 2024 | Dec 31, 2024 | 86.0× | – |
See a number that looks wrong?